Diabetes, obesity & metabolism|2026|Unknown authors
PMID: 41713957
14686 studies
Post-transplant metabolic management remains challenging, as immunosuppression exacerbates diabetes and obesity, threatening graft outcomes. While incretin-based therapies have transformed metabolic care, data on tirzepatide-a dual GIP/GLP-1 receptor…
AIM: To evaluate the effects of tirzepatide on physical function in adults with overweight or obesity. METHODS: We searched PubMed, Embase, and the Cochrane Library up to July 20, 2025 for randomized controlled trials (RCTs) comparing once-weekly tir…
AIM: Metabolic liver disease, including nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis, is a major cause of chronic liver dysfunction worldwide, creating an urgent need for effective treatments. This systematic literature r…
Heart failure with preserved ejection fraction (HFpEF) represents approximately half of all heart failure cases and poses a growing global health challenge driven by an ageing population and an increasing comorbidity burden. Once regarded as a condit…
Skin redundancy after massive weight loss often requires body contouring procedures such as abdominoplasty and mastopexy. Bariatric patients may face higher complication risks due to nutritional deficiencies. However, with proper management, includin…
PURPOSE OF REVIEW: This review examines the mechanistic pathways linking obesity and cardiovascular disease, with particular emphasis on recent advancements in pharmacologic therapies. It evaluates the cardiovascular effects of novel anti-obesity med…
Telehealth has become a mainstream healthcare delivery methods driven by advances in health technology, evolving patient preferences, and the need for more accessible and affordable care. While traditional pharmacy models remain effective, they face…
AIMS: Despite the established efficacy of tirzepatide in randomised controlled trials, real-world effectiveness data in Japanese patients remain limited. This study evaluated the real-world effectiveness and safety of tirzepatide in Japanese patients…
Obesity is a growing public health concern, closely linked to metabolic and cardiovascular complications. Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has shown substanti…
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used therapies for cardiovascular risk reduction in type 2 diabetes (T2D). With the emergence of the SURPASS-CVOT trial, tirzepatide (a dual GIP/GLP-1 receptor agonist) has e…
BACKGROUND: Tirzepatide, a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, has gained widespread use for the treatment of type 2 diabetes mellitus, obesity, and obstructive sleep apnea. Th…
Type 2 diabetes mellitus is closely associated with male reproductive dysfunction driven by oxidative stress, hormonal imbalance, and testicular cell damage. This study evaluated the effects of tirzepatide, a dual agonist of the glucose-dependent ins…
BACKGROUND: Euglycemic diabetic ketoacidosis (EDKA) is most commonly associated with sodium-glucose cotransporter-2 (SGLT2) inhibitors. However, emerging evidence suggests that glucagon-like peptide-1 (GLP-1) receptor agonists and dual incretin agent…
Diabetes mellitus encompasses chronic metabolic disorders marked by impaired insulin secretion, action, or both, with type 1 and type 2 diabetes presenting distinct mechanisms and therapeutic needs. Achieving durable glycemic control remains essentia…
BACKGROUND: Tirzepatide is anticipated to play a pivotal role in managing overweight/obesity and/or type 2 diabetes. Although prior studies have employed spontaneous reporting databases for large-scale safety monitoring of tirzepatide focusing on nov…